Recently, the FDA granted approved for alpelisib, a new PI3K inhibitor, in combination with fulvestrant for patients with metastatic HR+/HER2− breast cancer based on the positive results of the SOLAR-1 trial. Here, PIK3CA is linked to breast carcinoma.